Clostridium News and Research

RSS

Study finds low doses of vancomycin to be effective in treating serious C-difficile infection

Clostridium difficile infection (CDI) treatment in a hospital setting using low dose oral vancomycin showed similar effectiveness compared to high dose, according to a new study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University.

12 Sep 2013

Large study shows effective test for diagnosis of C-Diff infection

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile (C-Diff), a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in the United States.

4 Sep 2013

Study estimates total annual costs for five major health care-associated infections

A study estimates that total annual costs for five major health care-associated infections (HAIs) were $9.8 billion, with surgical site infections contributing the most to overall costs, according to a report published by JAMA Internal Medicine, a JAMA Network publication.

3 Sep 2013

Researchers pinpoint ways to counter effects of antibiotics-driven depletion of gut-dwelling bacteria

A new study by researchers at the Stanford University School of Medicine could help pinpoint ways to counter the effects of the antibiotics-driven depletion of friendly, gut-dwelling bacteria.

2 Sep 2013

Texas A&M University biologist receives federal grant to study Clostridium difficile

A Texas A&M University biologist has received a federal grant to study the fecal samples of hundreds of people to better understand the gut bacteria Clostridium difficile - the cause of some 14,000 deaths a year in America - and to help lay the basic science foundation to develop drugs to combat its deadly results.

30 Aug 2013

FDA extends PDUFA goal date for Auxilium Pharmaceuticals' sBLA for XIAFLEX

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has notified the Company that it is extending the Prescription Drug User Fee Act goal date for the Company's supplemental biologics license application for XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease from September 6, 2013 to December 6, 2013.

28 Aug 2013

Review Article examines FMT methodology as effective treatment for C. difficile infection

Fecal microbiota transplantation has emerged as a highly effective treatment for recurrent Clostridium difficile infection, with very early experience suggesting that it may also play a role in treating other gastrointestinal and non-GI diseases.

23 Aug 2013

Three winners announced for biomedical engineering design competition in DEBUT challenge

...

13 Aug 2013

Probiotic supplements have no effect on the incidence of diarrhoea in elderly patients

Probiotic supplements given to elderly patients on antibiotics appear to have no effect on the incidence of diarrhoea, a common and sometimes life-threatening side effect of using antibiotics for many elderly patients, according to a new study published in The Lancet.

9 Aug 2013

Decatur Memorial Hospital installs germ-zapping robots to kill bugs

As hospitals across the nation look for new and innovative ways to battle deadly pathogens and kill multi-drug resistant organisms that put patients at risk, Decatur Memorial Hospital (DMH) has taken a leap into the future with the installation of two germ-zapping robots that eliminate hard-to-kill bugs in hard-to-clean places.

3 Aug 2013

Jersey Shore hospital participates in clinical study of investigational vaccine for prevention of CDI

Mark Martens, M.D., chief of Obstetrics and Gynecology at Jersey Shore University Medical Center, announces that the hospital is participating in a clinical study to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI).

3 Aug 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

C. difficile bacteriophage provides new weapon to battle against superbugs

IFR microbiologists are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals.

19 Jul 2013

Infection control program and active surveillance can reduce incidence of impatient C. diff infections

A comprehensive infection control program combined with an active surveillance process significantly reduced the incidence of Clostridium difficile (C. diff) infections in a long-term acute care hospital, according to a study published in the Journal for Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality (NAHQ).

10 Jul 2013

Data on side effects of fidaxomicin not analysed appropriately

The antibiotic fidaxomicin (trade name: Dificlir) has been approved in Germany since December 2011 for the treatment of adults who have diarrhoea caused by Clostridium difficile.

3 Jul 2013

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Clostridium difficile (C. difficile) has reached an epidemic state and is the most common infectious cause of diarrhea in hospitals. Health care providers are seeing increased severity and recurrence rates of the infection. In response, Mayo Clinic has opened a C. difficile Clinic at the Rochester campus.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.

21 Jun 2013

Patients who receive antibiotics while in hospital may benefit from probiotics, say researchers

Patients in hospital who are on antibiotics may benefit from taking probiotics, according to researchers at St. Michael-s Hospital.

5 Jun 2013

Scientists work together to optimize the quality, availability of fecal microbiota transplants

Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.

4 Jun 2013